Research Capital analyst Andre Uddin maintained his “Speculative Buy” rating and US$ 5.50 target on NervGen Pharma (NervGen Pharma Stock Quote, Chart, News, Analysts, Financials NASDAQ:NGEN) after the company said it had completed its end-of-Phase 2 meeting with the U.S. Food and Drug Administration, clearing the way for the Phase 3 RESTORE trial in chronic tetraplegia. Uddin […]
In a March 31 report, Research Capital analyst Andre Uddin maintained his “Speculative Buy” rating and US$5.50 target on NervGen Pharma (NervGen Pharma Stock Quote, Chart, News, Analysts, Financials NASDAQ:NGEN), saying the firm remains focused primarily on the company’s clinical progress rather than near-term financial results. Uddin said NervGen recently completed its end-of-Phase 2 meeting […]
Share
Tweet
Share
